Jianbei Miao Miao (02161) subsidiary plans to acquire the entire issued share capital of Kenfukudo Chinese Medicine Group for HK$38 million

According to Zhitong Finance App News, Jianbei Miao (02161) announced that on June 16, 2025, the buyer Winner Win Limited (the company's indirect wholly-owned subsidiary) entered into a sales agreement with the seller Ever Development Holdings Limited. The buyer conditionally agreed to buy and the seller conditionally agreed to sell shares (that is, all issued share capital of the target company). According to the terms and conditions of the transaction agreement, the total cost was HK$38 million (subject to adjustment).

The target company, Kenfudang Chinese Medicine Group Limited, is a limited company incorporated in Hong Kong. The target company and its subsidiaries are mainly engaged in providing traditional Chinese medicine diagnosis services and selling health products.

According to the announcement, the Group expects the acquisition to bring sustainable revenue and profit growth, and expects to use the complementary advantages of the target group's business to bring significant synergy effects, including directly acquiring an existing customer base, providing a direct channel for promoting the Group's branded traditional Chinese medicines, and increasing brand recognition in the local market.